J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer is highlighting Johnson & Johnson's track record in developing novel cardiovascular drugs as a key asset in a co-development pact for its anti-thrombotic agent BAY 59-7939, announced Oct. 26
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product